Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin JE00B2QKY057
Ticker SHPGF
Company SHIRE
Currency $
Price
Aware Investor Index (AII) 0.0054
Recommendation STRONG SELL
P/E 44.82
ROE 3.54 %
Capitalization 57,456,000,000 $
Dividend Yield 0.49 %
P/S 3.79
AII Position 640
P/E Position 575
ROE Position 670
Capitalization Position 155
Dividend Yield Position 575
Sales 15,160,600,000 $
10-Year Average Earnings 1,281,890,000 $
Shares Outstanding 912,000,000
Equity 36,176,400,000 $
Dividend per Share 0.31 $
Industry Pharmaceutical
Country Jersey
SHIRE Investor Relations Web Site http://investors.shire.com/







Sales:

YEAR MONTH AMOUNT
2017 12 15,160,600,000.00 $
2016 12 11,396,600,000.00 $
2015 12 6,416,700,000.00 $
2014 12 6,022,100,000.00 $
2013 12 4,934,300,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 4,271,500,000.00 $
2016 12 327,400,000.00 $
2015 12 1,303,400,000.00 $
2014 12 3,405,500,000.00 $
2013 12 665,100,000.00 $
2012 12 745,400,000.00 $
2011 12 865,000,000.00 $
2010 12 588,000,000.00 $
2009 12 491,600,000.00 $
2008 12 156,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 36,176,400,000.00 $
2016 12 28,948,000,000.00 $
2015 12 9,829,100,000.00 $
2014 12 8,662,900,000.00 $
2013 12 5,366,000,000.00 $
2012 12 3,809,200,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 912,000,000
2016 12 776,200,000
2015 12 593,100,000
2014 12 591,300,000
2013 12 590,300,000
2012 12 593,500,000

 












Bloomberg News for SHIRE:



Google News for SHIRE:

Seeking Alpha - 8 Jan 2019
Reviewing The Takeda-Shire Merger
On 8 May 2018, Takeda Pharmaceutical Company Ltd (TAK) (OTCPK:TKPHF) proposed the acquisition of Shire Plc (SHPG) (OTCPK:SHPGF) ...
Seeking Alpha - 26 Apr 2018
Shire's Share Prices And Takeda's Deal Price Are Getting Closer
To get a better handle on what's going on between Takeda (OTCPK:TKPHF) ((4502 JP)) and Shire PLC (NASDAQ:SHPG) ((SHP LN)) and the ...
Seeking Alpha - 18 Dec 2018
Grifols Beginning To Look Enticing
Grifols (GRFS) is one of the largest plasma biotechs in the world. The company has been growing through M&A and by building new collection ...
Seeking Alpha - 19 May 2017
Shire Scores Another Rare Disease Win, But Will CSL Get There First?
Keenly awaited phase III data on Shire's (NASDAQ:SHPG) (OTCPK:SHPGF) hereditary angioedema (HAE) antibody, lanadelumab, appear to ...
Seeking Alpha - 4 Jan 2017
The Opportunities For Shire In Immunology: What The Market Is ...
Shire (NASDAQ:SHPG) (OTCPK:SHPGF) hosted an Investor Day on Thursday 10th November to discuss its business strategies and to help ...
Fortune - 8 Jan 2016
Shire's Merger With Baxalta Merger Is Nearly Done
Shire Pharmaceuticals Plc (shpgf, +0.00%) is preparing to announce it's buying U.S. peer Baxalta (bxlt, +0.00%) for roughly $32.5 billion as ...
Seeking Alpha - 5 Jan 2017
The Threats And Opportunities In Hereditary Angioedema: What ...
Hereditary Angioedema (HAE) is one of key growth franchise for Shire (NASDAQ:SHPG) (OTCPK:SHPGF), accounting for around $1.2B in ...
Seeking Alpha - 15 Dec 2018
Stocks To Watch: Time To Connect The Dots
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail ...
Seeking Alpha - 19 Sep 2018
Deciphera Pharmaceuticals: Will This ASCO Winner Repeat At ...
The share price has essentially doubled since last year's IPO. The valuation gap with larger competitor Blueprint Medicines appears enticing, ...
Fortune - 3 Jan 2016
Shire-Baxalta $32 Billion Merger Talks Said to Advance
Fortune reported earlier this year that Shire (shpgf, +0.00%) propositioned Baxalta with an unsolicited offer. When the company rejected Shire's ...


Back